User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes.

Primary tabs

Russo, Vincenzo Pilla, Lorenzo Lunghi, Francesca Crocchiolo, Roberto Greco, Raffaella Coulie, Pierre G. [UCL] Bregni, Marco

Cancer vaccines have recently been shown to induce some clinical benefits. The relationship between clinical activity and anti-vaccine T cell responses is somewhat controversial. Indeed, in many trials it has been documented that the induction of vaccine-specific T cells exceeds the clinical responses observed. Here, we evaluate immunological and clinical responses in 23 MAGE-A3(+) melanoma patients treated with autologous lymphocytes genetically engineered to express the tumor antigen MAGE-A3 and the viral gene product thymidine kinase of the herpes simplex virus (HSV-TK). HSV-TK was used as safety system in case of adverse events and as tracer antigen to monitor the immune competence of treated patients. The increase of anti-TK and anti-MAGE-A3 T-cells after vaccination was observed in 90 and 27% of patients, respectively. Among 19 patients with measurable disease, we observed a disease control rate of 26.3%, with one objective clinical response, and four durable, stable diseases. Three patients out of five with no evidence of disease (NED) at the time of vaccination remained NED after 73+, 70+ and 50+ months. Notably, we report that only patients experiencing MAGE-A3-specific immune responses showed a clinical benefit. Additionally, we report that responder and non-responder patients activate and expand T cells against the tracer antigen TK in a similar way, suggesting that local rather than systemic immune suppression might be involved in limiting clinically relevant antitumor immune responses.

Document type Article de périodique (Journal article)
Access type Accès restreint
Publication date 2013
Language Anglais
Journal information "International Journal of Cancer" - Vol. 132, no.11, p. 2557-66 (2013)
Peer reviewed yes
Publisher JohnWiley & Sons, Inc. ((United States) Hoboken)
issn 0020-7136
e-issn 1097-0215
Publication status Publié
Affiliation UCL - SSS/DDUV - Institut de Duve
MESH Subject Adult ; Humans ; Hypersensitivity, Delayed ; Liver Neoplasms ; Lung Neoplasms ; Male ; Melanoma ; Middle Aged ; Neoplasm Proteins ; Neoplasm Staging ; Skin Neoplasms ; Aged ; T-Lymphocytes ; Thymidine Kinase ; Antigens, Neoplasm ; Bone Neoplasms ; Cancer Vaccines ; Clinical Trials, Phase II as Topic ; Female ; Follow-Up Studies ; Genetic Therapy
Links
  1. Parmiani G., Castelli C., Dalerba P., Mortarini R., Rivoltini L., Marincola F. M., Anichini A., Cancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going?, 10.1093/jnci/94.11.805
  2. Rosenberg Steven A, Yang James C, Restifo Nicholas P, Cancer immunotherapy: moving beyond current vaccines, 10.1038/nm1100
  3. Rabinovich Gabriel A., Gabrilovich Dmitry, Sotomayor Eduardo M., Immunosuppressive Strategies that are Mediated by Tumor Cells, 10.1146/annurev.immunol.25.022106.141609
  4. Neller Michelle A., López J. Alejandro, Schmidt Christopher W., Antigens for cancer immunotherapy, 10.1016/j.smim.2008.09.006
  5. Kenter Gemma G., Welters Marij J.P., Valentijn A. Rob P.M., Lowik Margriet J.G., Berends-van der Meer Dorien M.A., Vloon Annelies P.G., Essahsah Farah, Fathers Lorraine M., Offringa Rienk, Drijfhout Jan Wouter, Wafelman Amon R., Oostendorp Jaap, Fleuren Gert Jan, van der Burg Sjoerd H., Melief Cornelis J.M., Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia, 10.1056/nejmoa0810097
  6. Tyagi Preeta, Mirakhur Beloo, MAGRIT: The Largest-Ever Phase III Lung Cancer Trial Aims to Establish a Novel Tumor-Specific Approach to Therapy, 10.3816/clc.2009.n.052
  7. Schwartzentruber Douglas J., Lawson David H., Richards Jon M., Conry Robert M., Miller Donald M., Treisman Jonathan, Gailani Fawaz, Riley Lee, Conlon Kevin, Pockaj Barbara, Kendra Kari L., White Richard L., Gonzalez Rene, Kuzel Timothy M., Curti Brendan, Leming Phillip D., Whitman Eric D., Balkissoon Jai, Reintgen Douglas S., Kaufman Howard, Marincola Francesco M., Merino Maria J., Rosenberg Steven A., Choyke Peter, Vena Don, Hwu Patrick, gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma, 10.1056/nejmoa1012863
  8. Ledford Heidi, A shot in the arm for cancer vaccines?, 10.1038/4641110a
  9. Tanne J. H., FDA approves prostate cancer "vaccine", 10.1136/bmj.c2431
  10. Fontana R., Bregni M., Cipponi A., Raccosta L., Rainelli C., Maggioni D., Lunghi F., Ciceri F., Mukenge S., Doglioni C., Colau D., Coulie P. G., Bordignon C., Traversari C., Russo V., Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients, 10.1182/blood-2008-07-168666
  11. Hoos Axel, Parmiani Giorgio, Hege Kristen, Sznol Mario, Loibner Hans, Eggermont Alexander, Urba Walter, Blumenstein Brent, Sacks Natalie, Keilholz Ulrich, Nichol Geoffrey, A Clinical Development Paradigm for Cancer Vaccines and Related Biologics : , 10.1097/01.cji.0000211341.88835.ae
  12. Wolchok J. D., Hoos A., O'Day S., Weber J. S., Hamid O., Lebbe C., Maio M., Binder M., Bohnsack O., Nichol G., Humphrey R., Hodi F. S., Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria, 10.1158/1078-0432.ccr-09-1624
  13. Hoos A., Eggermont A. M. M., Janetzki S., Hodi F. S., Ibrahim R., Anderson A., Humphrey R., Blumenstein B., Old L., Wolchok J., Improved Endpoints for Cancer Immunotherapy Trials, 10.1093/jnci/djq310
  14. Traversari C., Marktel S., Magnani Z., Mangia P., Russo V., Ciceri F., Bonini C., Bordignon C., The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies, 10.1182/blood-2006-04-015230
  15. Therasse Patrick, Arbuck Susan G., Eisenhauer Elizabeth A., Wanders Jantien, Kaplan Richard S., Rubinstein Larry, Verweij Jaap, Van Glabbeke Martine, van Oosterom Allan T., Christian Michaele C., Gwyther Steve G., New Guidelines to Evaluate the Response to Treatment in Solid Tumors, 10.1093/jnci/92.3.205
  16. van Baren Nicolas, Bonnet Marie-Claude, Dréno Brigitte, Khammari Amir, Dorval Thierry, Piperno-Neumann Sophie, Liénard Danielle, Speiser Daniel, Marchand Marie, Brichard Vincent G., Escudier Bernard, Négrier Sylvie, Dietrich Pierre-Yves, Maraninchi Dominique, Osanto Susanne, Meyer Ralf G., Ritter Gerd, Moingeon Philippe, Tartaglia Jim, van der Bruggen Pierre, Coulie Pierre G., Boon Thierry, Tumoral and Immunologic Response After Vaccination of Melanoma Patients With an ALVAC Virus Encoding MAGE Antigens Recognized by T Cells, 10.1200/jco.2005.08.375
  17. Lara Primo N., Redman Mary W., Kelly Karen, Edelman Martin J., Williamson Stephen K., Crowley John J., Gandara David R., Disease Control Rate at 8 Weeks Predicts Clinical Benefit in Advanced Non–Small-Cell Lung Cancer: Results From Southwest Oncology Group Randomized Trials, 10.1200/jco.2007.13.0344
  18. Fleischhauer, J Immunol, 159, 2513 (1997)
  19. Germeau Catherine, Ma Wenbin, Schiavetti Francesca, Lurquin Christophe, Henry Emmanuelle, Vigneron Nathalie, Brasseur Francis, Lethé Bernard, De Plaen Etienne, Velu Thierry, Boon Thierry, Coulie Pierre G., High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens, 10.1084/jem.20041379
  20. Lurquin Christophe, Lethé Bernard, De Plaen Etienne, Corbière Véronique, Théate Ivan, van Baren Nicolas, Coulie Pierre G., Boon Thierry, Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen, 10.1084/jem.20041378
  21. Haight, Handbook of the Poisson distribution (1967)
  22. Hacein-Bey-Abina S., LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1, 10.1126/science.1088547
  23. Walter Steffen, Weinschenk Toni, Stenzl Arnulf, Zdrojowy Romuald, Pluzanska Anna, Szczylik Cezary, Staehler Michael, Brugger Wolfram, Dietrich Pierre-Yves, Mendrzyk Regina, Hilf Norbert, Schoor Oliver, Fritsche Jens, Mahr Andrea, Maurer Dominik, Vass Verona, Trautwein Claudia, Lewandrowski Peter, Flohr Christian, Pohla Heike, Stanczak Janusz J, Bronte Vincenzo, Mandruzzato Susanna, Biedermann Tilo, Pawelec Graham, Derhovanessian Evelyna, Yamagishi Hisakazu, Miki Tsuneharu, Hongo Fumiya, Takaha Natsuki, Hirakawa Kosei, Tanaka Hiroaki, Stevanovic Stefan, Frisch Jürgen, Mayer-Mokler Andrea, Kirner Alexandra, Rammensee Hans-Georg, Reinhardt Carsten, Singh-Jasuja Harpreet, Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival, 10.1038/nm.2883
  24. Russo Vincenzo, Cipponi Arcadi, Raccosta Laura, Rainelli Cristina, Fontana Raffaella, Maggioni Daniela, Lunghi Francesca, Mukenge Sylvain, Ciceri Fabio, Bregni Marco, Bordignon Claudio, Traversari Catia, Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity, 10.1172/jci30605
  25. Riddell Stanley R., Elliott Mark, Lewinsohn Deborah A., Gilbert Mark J., Wilson Linda, Manley Sara A., Lupton Stephen D., Overell Robert W., Reynolds Thomas C., Corey Lawrence, Greenberg Philip D., T–cell mediated rejection of gene–modified HIV–specific cytotoxic T lymphocytes in HIV–infected patients, 10.1038/nm0296-216
  26. Berger C., Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation, 10.1182/blood-2005-08-3503
  27. Wang Helen Y, Lee Dean A, Peng Guangyong, Guo Zhong, Li Yanchun, Kiniwa Yukiko, Shevach Ethan M, Wang Rong-Fu, Tumor-Specific Human CD4+ Regulatory T Cells and Their Ligands, 10.1016/s1074-7613(03)00359-5
  28. Marincola Francesco M., Jaffee Elizabeth M., Hicklin Daniel J., Ferrone Soldano, Escape of Human Solid Tumors from T–Cell Recognition: Molecular Mechanisms and Functional Significance, Advances in Immunology (1999) ISBN:9780120224746 p.181-273, 10.1016/s0065-2776(08)60911-6
  29. Garrido Federico, Algarra Ignacio, García-Lora Angel M., The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible “hard” lesions, 10.1007/s00262-010-0893-2
  30. Tacken Paul J., de Vries I. Jolanda M., Torensma Ruurd, Figdor Carl G., Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting, 10.1038/nri2173
  31. Russo Vincenzo, Bondanza Attilio, Ciceri Fabio, Bregni Marco, Bordignon Claudio, Traversari Catia, Bonini Chiara, A dual role for genetically modified lymphocytes in cancer immunotherapy, 10.1016/j.molmed.2011.12.003
  32. Bonini C., Grez M., Traversari C., Ciceri F., Marktel S., Ferrari G., Dinauer M., Sadat M., Aiuti A., Deola S., Radrizzani M., Hagenbeek A., Apperley J., Ebeling S., Martens A., Kolb H.J., Weber M., Lotti F., Grande A., Weissinger E., Bueren J.A., Lamana M., Falkenburg J.H.F., Heemskerk M.H.M., Austin T., Kornblau S., Marini F., Benati C., Magnani Z., Cazzaniga S., Toma S., Gallo-Stampino C., Introna M., Slavin S., Greenberg P.D., Bregni M., Mavilio F., Bordignon C., Safety of retroviral gene marking with a truncated NGF receptor, 10.1038/nm0403-367
  33. Recchia A., Bonini C., Magnani Z., Urbinati F., Sartori D., Muraro S., Tagliafico E., Bondanza A., Stanghellini M. T. L., Bernardi M., Pescarollo A., Ciceri F., Bordignon C., Mavilio F., Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells, 10.1073/pnas.0507496103
  34. Newrzela S., Cornils K., Li Z., Baum C., Brugman M. H., Hartmann M., Meyer J., Hartmann S., Hansmann M.-L., Fehse B., von Laer D., Resistance of mature T cells to oncogene transformation, 10.1182/blood-2007-12-128751
  35. Vesely Matthew D., Kershaw Michael H., Schreiber Robert D., Smyth Mark J., Natural Innate and Adaptive Immunity to Cancer, 10.1146/annurev-immunol-031210-101324
  36. Chaux Pascal, Vantomme Valérie, Coulie Pierre, Boon Thierry, van der Bruggen Pierre, Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer, 10.1002/(sici)1097-0215(19980812)77:4<538::aid-ijc11>3.0.co;2-2
  37. Gajewski T. F., Identifying and Overcoming Immune Resistance Mechanisms in the Melanoma Tumor Microenvironment, 10.1158/1078-0432.ccr-05-2517
  38. Coulie Pierre G, Connerotte Thierry, Human tumor-specific T lymphocytes: does function matter more than number?, 10.1016/j.coi.2005.03.002
  39. Eggermont Alexander M.M., Schadendorf Dirk, Melanoma and Immunotherapy, 10.1016/j.hoc.2009.03.009
Bibliographic reference Russo, Vincenzo ; Pilla, Lorenzo ; Lunghi, Francesca ; Crocchiolo, Roberto ; Greco, Raffaella ; et. al. Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes.. In: International Journal of Cancer, Vol. 132, no.11, p. 2557-66 (2013)
Permanent URL http://hdl.handle.net/2078.1/130005